Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2003;107:514-516
doi: 10.1161/01.CIR.0000053944.35059.FA
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Stevenson, W. G.
Right arrow Articles by Epstein, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stevenson, W. G.
Right arrow Articles by Epstein, L. M.
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Cardiac Arrest
*Heart Failure
*Pacemakers and Implantable Defibrillators
Related Collections
Right arrow Electrophysiology
Right arrow Congestive
Right arrow Electrocardiology
Right arrow Ablation/ICD/surgery
Right arrow Arrhythmias, clinical electrophysiology, drugs
Right arrowRelated Article

(Circulation. 2003;107:514.)
© 2003 American Heart Association, Inc.

Predicting Sudden Death Risk for Heart Failure Patients in the Implantable Cardioverter-Defibrillator Age

William G. Stevenson, MD; Laurence M. Epstein, MD

From The Cardiovascular Division, Department of Internal Medicine, Brigham and Women’s Hospital, Boston, Mass.

Correspondence to William G. Stevenson, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115. E-mail wstevenson@partners.org


Key Words: Editorials • death, sudden • heart failure • defibrillation


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 

One-third to one-half of patients with chronic, dilated heart failure will die suddenly or be resuscitated from a cardiac arrest or sustained ventricular tachycardia (VT).1–3 Implantable cardioverter-defibrillators (ICDs) offer excellent protection from sudden death by providing effective termination of the arrhythmia when it occurs, but they are not without problems. Approximately one-third of patients will experience some adverse effect, including inappropriate shocks, lead problems, and infection.4,5 The implantation and testing procedure occasionally precipitates hemodynamic deterioration.6 DDD or VVI pacing from the right ventricular lead of the ICD may have adverse hemodynamic effects, including increasing dyssynchrony of left ventricular contraction, and may have contributed to the aggravation of heart failure observed in the Multicenter Automatic Defibrillator Implantation Trial II (MADIT II).7,8

See p 565

As with any therapy, wider use in lower risk patients increases the number of patients who might not benefit but who still suffer adverse effects. On the other hand, many sudden deaths will be prevented, and the balance, to this point, has been positive. The substantial costs of the ICD hardware, implantation, and follow-up are also a concern. Thus, identifying those patients with depressed ventricular function who are most likely to benefit, or perhaps more importantly, those who are unlikely to benefit, is of interest.

The development of tests to identify patients at high risk for fatal arrhythmias typically follows a progression (Table). Retrospective studies determine if a positive test is more common in known high-risk groups (eg, cardiac arrest survivors) compared with lower risk . . . [Full Text of this Article]


Related Article:

Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients
Maria Teresa La Rovere, Gian Domenico Pinna, Roberto Maestri, Andrea Mortara, Soccorso Capomolla, Oreste Febo, Roberto Ferrari, Mariella Franchini, Marco Gnemmi, Cristina Opasich, Pier Giorgio Riccardi, Egidio Traversi, and Franco Cobelli
Circulation 2003 107: 565-570. [Abstract] [Full Text]



This article has been cited by other articles:


Home page
EuropaceHome page
E. M. Kanoupakis, E. G. Manios, and P. E. Vardas
Predicting future shocks in implantable cardioverter defibrillator recipients: the role of biomarkers
Europace, November 1, 2009; 11(11): 1434 - 1439.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc AHome page
H. V Huikuri, J. S Perkiomaki, R. Maestri, and G. D. Pinna
Clinical impact of evaluation of cardiovascular control by novel methods of heart rate dynamics
Phil Trans R Soc A, April 13, 2009; 367(1892): 1223 - 1238.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
J. P. Singh, W. J. Hall, S. McNitt, H. Wang, J. P. Daubert, W. Zareba, J. N. Ruskin, A. J. Moss, and and the MADIT-II Investigators
Factors Influencing Appropriate Firing of the Implanted Defibrillator for Ventricular Tachycardia/Fibrillation: Findings From the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II)
J. Am. Coll. Cardiol., November 1, 2005; 46(9): 1712 - 1720.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
P. Bordier, S. Garrigue, S. Reuter, P. Bordachar, and J. Clementy
Death During Polysomnography of a Patient With Cheyne-Stokes Respiration, Respiratory Acidosis, and Chronic Heart Failure
Chest, November 1, 2004; 126(5): 1698 - 1700.
[Abstract] [Full Text] [PDF]